Skip to content
value.today

Kinnate Biopharma Inc.

🇺🇸 San Diego, California, USAPharmaceuticalsFounded 2018
Total raised
$173 M
2 rounds on record
Latest round
$98 M
Jul 2020
First round on record
Dec 2019
Today
Private
No later event on record

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Kinnate Biopharma Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jul 2020$98 MNo. 2$50 to $250 million

Kinnate Biopharma Inc.: Raise no. 2, Jul 2020

Investors in this round

24 investors had bought by the notice of Aug 31, 2020: 24 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 9 investors are named for Kinnate Biopharma Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$98 M of $98 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Mark W. Meltz · Executive Officer
  • Nima W. Farzan · Executive Officer, Director
  • Carl W. Gordon · Director
  • Dean W. Mitchell · Director
  • Jim W. Tananbaum · Director
  • Keith W. Flaherty · Director
  • Laurie W. Smaldone Alsup · Director
  • Michael W. Rome · Director
  • Stephen W. Kaldor · Director, Promoter

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Mark Meltz, Chief Operating Officer. Newest notice filed Aug 31, 2020 (1 amendment). Read the notice at the SEC.

equitySEC
Dec 2019$75 MNo. 1$50 to $250 million

Kinnate Biopharma Inc.: Raise no. 1, Dec 2019

Investors in this round

5 investors had bought by the notice of Dec 23, 2019: 5 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 9 investors are named for Kinnate Biopharma Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$75 M of $75 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in California

People named in the notice

  • Eric W. Murphy · Executive Officer, Director
  • Stephen W. Kaldor · Executive Officer, Director, Promoter
  • Bret W. Zbar · Director
  • Carl W. Gordon · Director
  • Michael W. Rome · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Stephen W. Kaldor, Chief Executive Officer. Newest notice filed Dec 23, 2019. Read the notice at the SEC.

equitySEC

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Kinnate Biopharma Inc. chose not to state its revenue in its newest notice of a funding round (Aug 2020).

    SEC Form D · Aug 2020

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Aug 2020

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

9 named in official filings. Open an investor to see everything it has backed.

Investors in Kinnate Biopharma Inc.
InvestorKindAmountRoundRoleSource
Foresite Capital Fund IV, L.P.Fund or asset managernot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Foresite Capital Fund V, L.P.Fund or asset managernot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Foresite Capital Management IV, LLCFund or asset managernot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Foresite Capital Management V, LLCFund or asset managernot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Foresite Capital Opportunity Fund V, L.P.Fund or asset managernot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Foresite Capital Opportunity Management V, LLCFund or asset managernot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Orbimed Advisors LLCFund or asset managernot statednot statedHeld Series A, B and C preferred stock, 10% owner, director (Form 3, 2020)SEC Form 3
OrbiMed Capital GP VII LLCFund or asset managernot statednot statedHeld Series A, B and C preferred stock, 10% owner, director (Form 3, 2020)SEC Form 3
OrbiMed Genesis GP LLCOthernot statednot statedHeld Series A, B and C preferred stock, 10% owner, director (Form 3, 2020)SEC Form 3

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Kinnate Biopharma Inc.
NameRoleNamed in
Mark W. MeltzExecutive officerAug 2020
Nima W. FarzanExecutive officerAug 2020
Eric W. MurphyExecutive officerDec 2019
Stephen W. KaldorExecutive officerDec 2019
Carl W. GordonDirectorAug 2020
Dean W. MitchellDirectorAug 2020
Jim W. TananbaumDirectorAug 2020
Keith W. FlahertyDirectorAug 2020
Laurie W. Smaldone AlsupDirectorAug 2020
Michael W. RomeDirectorAug 2020
Nima W. FarzanDirectorAug 2020
Stephen W. KaldorDirectorAug 2020
Bret W. ZbarDirectorDec 2019
Eric W. MurphyDirectorDec 2019
Stephen W. KaldorPromoterAug 2020